- NovoCodex responsible for funding Ambrx’s Phase 1 development of ARX305 - SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback